Tudor–Eliade Ciuleanu

39.8k total citations · 9 hit papers
202 papers, 17.3k citations indexed

About

Tudor–Eliade Ciuleanu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tudor–Eliade Ciuleanu has authored 202 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Oncology, 127 papers in Pulmonary and Respiratory Medicine and 30 papers in Molecular Biology. Recurrent topics in Tudor–Eliade Ciuleanu's work include Lung Cancer Treatments and Mutations (93 papers), Lung Cancer Research Studies (55 papers) and Colorectal Cancer Treatments and Studies (47 papers). Tudor–Eliade Ciuleanu is often cited by papers focused on Lung Cancer Treatments and Mutations (93 papers), Lung Cancer Research Studies (55 papers) and Colorectal Cancer Treatments and Studies (47 papers). Tudor–Eliade Ciuleanu collaborates with scholars based in Romania, United States and Spain. Tudor–Eliade Ciuleanu's co-authors include José Rodrigues Pereira, Sumitra Thongprasert, Mircea Dediu, Frances A. Shepherd, Vera Hirsh, Lesley Seymour, Andrea Bezjak, Eng Huat Tan, Michael Smylie and P. Santabárbara and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Tudor–Eliade Ciuleanu

194 papers receiving 16.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Frances A. Shepherd, Tudor–Eliade Ciuleanu et al. profile →
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 1.7k citations Nick Thatcher, Tudor–Eliade Ciuleanu et al. profile →
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 917 citations Tudor–Eliade Ciuleanu, Aleksandra Szczęsna et al. profile →
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

2009 832 citations Tudor–Eliade Ciuleanu, Valentina Tzekova et al. profile →
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Tudor–Eliade Ciuleanu, Eric Van Cutsem et al. profile →
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

2006 570 citations Nick Thatcher, Tudor–Eliade Ciuleanu et al. Journal of Clinical Oncology profile →
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations Tudor–Eliade Ciuleanu et al. profile →
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Aleksandra Szczęsna et al. profile →

Peers

Countries citing papers authored by Tudor–Eliade Ciuleanu

Since Specialization

Citations

This map shows the geographic impact of Tudor–Eliade Ciuleanu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tudor–Eliade Ciuleanu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tudor–Eliade Ciuleanu more than expected).

Fields of papers citing papers by Tudor–Eliade Ciuleanu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tudor–Eliade Ciuleanu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tudor–Eliade Ciuleanu. The network helps show where Tudor–Eliade Ciuleanu may publish in the future.

Co-authorship network of co-authors of Tudor–Eliade Ciuleanu

This figure shows the co-authorship network connecting the top 25 collaborators of Tudor–Eliade Ciuleanu. A scholar is included among the top collaborators of Tudor–Eliade Ciuleanu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tudor–Eliade Ciuleanu. Tudor–Eliade Ciuleanu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy 2025 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Iulia Andraș, (unknown), (unknown), Antonio De Leo, Tudor–Eliade Ciuleanu, Nicolae Crişan, Camelia Alexandra Coadǎ	0
2	Immune Cell–Cytokine Interplay in NSCLC and Melanoma: A Pilot Longitudinal Study of Dynamic Biomarker Interactions 2025 ·SHILAP Revista de lepidopterología ·(unknown), Olga Şoriţău, Ioana Brie, Maria Perde‐Schrepler, Piroska Virág, (unknown), Tudor–Eliade Ciuleanu, Cosmin Andrei Cismaru	0
3	Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute 2024 ·Cancers ·(unknown), Tudor–Eliade Ciuleanu, (unknown), Cătălin Vlad, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
4	First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma. 2024 ·Journal of Clinical Oncology ·Elena Garralda, (unknown), Guillermo de Velasco, (unknown), (unknown), (unknown), Víctor Moreno, Valentina Boni, Andrés Cervantes, Valentina Gambardella, Tudor–Eliade Ciuleanu, (unknown), Delvys Rodríguez‐Abreu, Guzmán Alonso, Laurenţia Galeş, D. H. Jones, Abhay Patki, Ignacio Melero	5
5	Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. 2024 ·Journal of Clinical Oncology ·Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker, Stéphanie Bordenave-Juchereau, Manuel Cobo, Óscar Juan, Niels Reinmuth, Eduardo Richardet, Enriqueta Felip, J. Menezes, Ying Cheng, Hideaki Mizutani, David P. Carbone, Shun Lü, Thomas John, (unknown), Javed Mahmood, Nan Hu, Laura J. Eccles, Luis Paz‐Ares	6
6	5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity 2024 ·Medicine and Pharmacy Reports ·Raluca Munteanu, Cristian Moldovan, Adrian Bogdan Țigu, Rareş Drulă, (unknown), Lorand Magdo, Ancuța Jurj, Lajos Ráduly, Liviuţa Budişan, Radu Pîrlog, Alin Moldovan, Alina‐Andreea Zimța, Elena Ioana Braicu, (unknown), (unknown), (unknown), Diana Gulei, Tudor–Eliade Ciuleanu	1
7	MicroRNAs expression profile in chemotherapy-induced cardiotoxicity in non-small cell lung cancer using a co-culture model 2023 ·SHILAP Revista de lepidopterología ·(unknown), Oana Zănoagă, Liviuţa Budişan, Ancuța Jurj, Lajos Ráduly, Laura Pop, Cristina Ciocan, Radu Pîrlog, Cornelia Braicu, Tudor–Eliade Ciuleanu, Ioana Berindan‐Neagoe	2
8	Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses 2023 ·Cancer Research ·Quincy S. Chu, Tudor–Eliade Ciuleanu, Rodryg Ramlau, Daniel J. Renouf, Rosalyn A. Juergens, Ewa Kalinka‐Warzocha, Piotr Sawrycki, Jonathan L. Bramson, Brad H. Nelson, (unknown), Daniela A. Sahlender, (unknown), Elisabeth Rouits, (unknown), Franck Brichory, (unknown), M Schenker, Glenwood Goss	1
9	Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients 2022 ·International Journal of Environmental Research and Public Health ·(unknown), Tudor–Eliade Ciuleanu, (unknown), Oana Pascu, (unknown), (unknown), (unknown), Cristina Oprean, Laura Pop, Ioana Berindan‐Neagoe, (unknown), Alexandru Eniu	12
10	Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT) 2022 ·Current Oncology ·(unknown), (unknown), Mircea Dediu, Ivan Donev, (unknown), (unknown), Tudor–Eliade Ciuleanu, Adam Płużański	6
11	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer 2021 ·OncoTargets and Therapy ·(unknown), Olga Şoriţău, (unknown), Tudor–Eliade Ciuleanu, Mihnea Zdrenghea	6
12	Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe 2020 ·Radiology and Oncology ·Milada Zemanová, Marko Jakopović, (unknown), (unknown), Martina Vrankar, (unknown), Tudor–Eliade Ciuleanu, Davorin Radosavljević, Krisztina Bogos, Sergiusz Nawrocki	2
13	NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC 2016 ·Annals of Oncology ·Mark A. Socinski, Ben Creelan, Leora Horn, Martin Reck, Luis Paz‐Ares, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, William J. Geese, Prabhu Bhagavatheeswaran, (unknown), David P. Carbone	86
14	Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study 2015 ·Journal of Thoracic Oncology ·Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczęsna, W Szafrański, Rodryg Ramlau, Beatrix Bálint, Andrzej Każarnowicz, Olivier Molinier, H. Depenbrock, Shivani Nanda, Luis Paz‐Ares, Nick Thatcher	1
15	KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis 2014 ·Annals of Oncology ·Marc Peeters, Kelly S. Oliner, Timothy Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, A. H. Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Hua Yu, A. Scott Jung, R. Sidhu, Scott D. Patterson	2
16	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer breakdown → 2010 ·Journal of Clinical Oncology ·Marc Peeters, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert	755
17	Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia 2010 ·American Journal of Hematology ·Michael Auerbach, Peter T. Silberstein, R. Timothy Webb, (unknown), Tudor–Eliade Ciuleanu, James Shao, Kenneth R. Bridges	71
18	A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens 2010 ·Journal of Thoracic Oncology ·John D. Hainsworth, C. Cebotaru, (unknown), Tudor–Eliade Ciuleanu, (unknown), Phillip J. Stella, (unknown), G. Pover, Clive Morris, Valentina Tzekova	134
19	Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer 2009 ·Annals of Oncology ·(unknown), A. Roszak, Mariusz Bidziński, Tudor–Eliade Ciuleanu, Thomas Högberg, Marek Z. Wojtukiewicz, Andrés Poveda, Karin Boman, Anneke M. Westermann, Claudia Lebedinsky	56
20	A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial 2004 ·Journal of Clinical Oncology ·Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Ee Hong Tan, Vera Hirsh, S. Thongprasert, Andrea Bezjak, Dongping Tu, (unknown), Lesley Seymour	212

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact